Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is a leading player in the respiratory care device market, with strong growth potential driven by increasing incidences of sleep apnea, aging population, and prevalence of obesity. The company's focus on digital health and cloud-connected medical devices sets it apart from competitors and positions it for success in the out-of-hospital setting. Its strong financial performance in recent quarters, with revenue of $1.42B (+9% y/y ex-FX) and an impressive gross margin of 62.3%, demonstrates its efficient operations and cost-cutting initiatives. However, concerns over GLP-1 drugs and competition in the wearables market pose some risks for the company's success.

Bears say

ResMed is performing well with solid growth in revenues and a steady increase in gross margin, driven by strong mask sales and cost optimization efforts. However, there are risks to their target price, including potential disruptions from GLP-1 therapeutics and continued competition, as well as the uncertainty of how the company's recent acquisitions will contribute to their profitability. Additionally, the current market dynamics and outlook for the company's products may impact their future growth potential.

ResMed (RMD) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 10 analysts, ResMed (RMD) has a Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $292.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $292.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.